Search results
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Brown Advisory Inc.
ETF DAILY NEWS· 22 hours agoBrown Advisory Inc. cut its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.7% during the fourth quarter, HoldingsChannel reports ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron ...
NBC 10 - FOX 14 Monroe· 1 day agoPomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 9 hours agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory ...
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
The Motley Fool via AOL· 20 hours agoNvidia (NASDAQ: NVDA), Netflix (NASDAQ: NFLX), and Regeneron Pharmaceuticals (NASDAQ: REGN) have...
US FDA approves Biocon unit’s biosimilar to blockbuster eye drug Eylea
KFGO· 4 days ago(Reuters) - The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoNEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymeworks Inc. (NASDAQ: ...
Regeneron CEO Leonard Schleifer sells over $22 million in company stock By Investing.com
Investing.com· 6 days agoIn a recent transaction, Leonard S. Schleifer, the CEO and Co-Chair of Regeneron (NASDAQ:REGN)...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 4 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
With analysts seeing a likely US recession, here are 4 recession proof stocks to consider | Invezz...
Invezz· 2 days agoAt the beginning of 2024, Citigroup chief US economist predicted in a CNBC interview that the USA...
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International...
Yucaipa News Mirror· 6 days agoTARRYTOWN, N.Y. and WASHINGTON, May 17, 2024 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc....